Chemoradiotherapy followed by durvalumab in patients with unresectable advanced non‐small cell lung cancer: Management of adverse events

Chemoradiotherapy followed by durvalumab in patients with unresectable advanced non‐small cell lung cancer: Management of adverse events

Background Chemoradiotherapy followed by durvalumab is the standard treatment for the patients with local advanced non‐small cell lung cancer (NSCLC). There is a real‐world data about the management of adverse events, such as pneumonitis, according to the different institutions. Here, we present the...

Full description

Saved in:
Bibliographic Details
Main Authors: Yu Miura, Atsuto Mouri, Kyoichi Kaira, Ou Yamaguchi, Ayako Shiono, Kosuke Hashimoto, Fuyumi Nishihara, Shun Shinomiya, Tomoe Akagami, Yoshitake Murayama, Takanori Abe, Shin‐ei Noda, Shingo Kato, Kunihiko Kobayashi, Hiroshi Kagamu
Format: Article
Language:English
Published: Wiley 2020-05-01
Series:Thoracic Cancer
Subjects:
Chemoradiotherapy
durvalumab
non‐small cell lung cancer
radiation pneumonitis
real‐world experience
Online Access:https://doi.org/10.1111/1759-7714.13394
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1111/1759-7714.13394

Similar Items